All In Biotech

Drug Trial Radar · NCT03914326

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 9,651 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,651

Actual

Start

Jun 17, 2019

Primary completion

Aug 23, 2024

Study completion Aug 23, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone call with the study doctor. Women cannot be in the study if pregnant, breast-feeding or if they plan to become pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • SemaglutideDrug

    Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state

  • Placebo (semaglutide)Drug

    Placebo tablets to be taken with water at the same time every morning in a fasting state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal StrokeTime frame: From randomisation (week 0) up to week 265

Locations

492 sites in 34 countries. Site status is shown where the registry gives one.

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama

  • Medical Investigations, Inc.

    Little Rock, Arkansas

  • Unity Health-Searcy Medical Center

    Searcy, Arkansas

  • B&K Medical Research Center

    Fresno, California

  • University of Vermont Medical Center

    Fullerton, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Diabetes & Endocrine Associates

    La Mesa, California

  • First Valley Medical Group

    Lancaster, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Facey Medical Foundation

    Mission Hills, California

  • Monterey Endocrine & Diabetes Institute, Inc

    Monterey, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • San Diego Family Care

    San Diego, California

  • Lundquist Inst-Biomed Innovtn

    Torrance, California

  • Coastal Metabolic Research Center

    Ventura, California

  • Rocky Mount Reg VA Med-DN

    Aurora, Colorado

  • Creekside Endocrine Associates, PC

    Denver, Colorado

  • New West Physicians,Inc.

    Golden, Colorado

  • East Coast Medical Associates, Inc.

    Boca Raton, Florida

  • Suncoast Clin Res Port Richey

    New Port Richey, Florida

  • AdventHealth Diab Inst

    Orlando, Florida

  • Ellipsis Group

    Alpharetta, Georgia

  • Physicians Research Assoc. LLC

    Lawrenceville, Georgia

  • Endo Res Solutions Inc

    Roswell, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Rocky Mountain Diab&Osteo Ctr

    Idaho Falls, Idaho

  • Clinical Invest Special_Gurnee

    Gurnee, Illinois

  • American Health Network of IN LLC_Franklin

    Franklin, Indiana

  • American Health Network of Indiana, LLC_Greenfield

    Greenfield, Indiana

  • Franciscan Health Michigan City

    Michigan City, Indiana

  • American Health Network of IN LLC

    Muncie, Indiana

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • The Research Group of Lexington LLC

    Lexington, Kentucky

  • Robley Rex VA Medical Center

    Louisville, Kentucky

  • L-MARC Research Center

    Louisville, Kentucky

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Ileana J Tandron APMC

    Slidell, Louisiana

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan

  • Methodist Phys. Clinic

    Omaha, Nebraska

  • Univ of Nebraska Medical CTR

    Omaha, Nebraska

Showing 40 of 492 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.